K Number
K151780
Device Name
CAAS Workstation
Date Cleared
2016-03-11

(254 days)

Product Code
Regulation Number
892.1600
Reference & Predicate Devices
Predicate For
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

CAAS Workstation is a modular software product intended to be used by or under supervision of a cardiologist or radiologist in order to aid in reading, co-registering and interpreting cardiovascular X-Ray images to support diagnoses and for assistance during intervention of cardiovascular conditions.

CAAS Workstation features segmentation of cardiovascular structures, 3D reconstruction of vessel segments and catheter path based on multiple angiographic images, measurement and reporting tools to facilitate the following use:

  • Calculate the dimensions of cardiovascular structures;
  • Quantify stenosis in coronary and peripheral vessels;
  • Quantify the motion of the left and right ventricular wall;
  • Perform density measurements;
  • Determine C-arm position for optimal imaging of cardiovascular structures;
  • Enhance stent visualization and measure stent dimensions;
  • Co-registration of angiographic X-Ray images with IVUS and OCT images.

CAAS Workstation is intended to be used by or under supervision of a cardiologist or radiologist. When the results provided by CAAS Workstation are used in a clinical setting to support diagnoses and for assistance during intervention of cardiovascular conditions, the results are explicitly not to be regarded as the sole, irrefutable basis for clinical decision making.

Device Description

CAAS Workstation is designed as a stand-alone modular software product for viewing and quantification of X-ray angiographic images intended to run on a PC with a Windows operating system. CAAS Workstation contains the analysis modules QCA, QCA3D, QVA, LVA, RVA and StentEnhancer of the previously cleared predicate device CAAS Workstation (K133993) for calculating dimensions of coronary and peripheral vessels and the left and right ventricles, quantification of stenosis, performing density measurements, determination of optimal C-arm position for imaging of vessel segments and functionality to enhance the visualization of a stent and to measure stent dimension. Semi-automatic contour detection forms the basis for the analyses.

Functionality to co-register X-ray angiographic images and intravascular imaging techniques (such as intravascular ultrasound and optical coherence tomography) is added by means of the analysis module IV-LINQ. With co-registration a common frame of intravascular imaging techniques with X-ray angiographic images is provided using a three-dimensional model. This functionality is based on the Volcano Angio-IVUS Mapping system (K060483).

In the IV LINQ workflow the user has to select two angiographic X-ray images in DICOM format. The user indicates a catheter path starting at the imaging tip. This path can be optimized manually by adding, deleting or moving control point on the drawn path. After the catheter path is drawn in both angiographic X-ray images, a 3D reconstruction of the catheter path is calculated.

The user then has to select one IVUS or OCT dataset in DICOM format or the data is streamed from the intravascular imaging console with a DVI streamer. The IVUS or OCT pullback must be acquired using a motorized pullback device. After the 3D catheter path from X-ray angiographic images is calculated and the IVUS or OCT pullback is loaded, IV-LINQ co-registers each IVUS or OCT frame with a position on the 3D catheter path using a distance mapping algorithm. On intravascular images diameter and area measurements can be performed.

The quantitative results of CAAS Workstation support diagnosis and intervention of cardiovascular conditions. The analysis results are available on screen, and can be exported in various electronic formats. The functionality is independent of the type of vendor acquisition equipment.

AI/ML Overview

The provided text describes the CAAS Workstation and its regulatory submission. It mentions performance data and validation efforts but does not provide explicit acceptance criteria in a table format, nor does it detail a specific study with quantitative results proving adherence to such criteria.

However, I can extract the information provided regarding the device's validation and testing:

1. Table of Acceptance Criteria and Reported Device Performance:

The document does not provide a table of acceptance criteria with corresponding performance metrics. Instead, it offers a general statement about performance:

Acceptance Criteria CategoryReported Device Performance
System RequirementsSystem testing showed that the system requirements were implemented correctly.
Algorithm FunctioningFor each analysis workflow, a validation approach is created, and the proper functioning of the algorithms is validated.
Regression TestingFor analysis workflows already implemented in earlier versions of CAAS Workstation, regression testing is performed to verify equivalence in numerical results.
Distance Mapping Algorithm (IV LINQ)The validation of the distance mapping algorithm used in IV LINQ demonstrated that the length on which co-registration is based meets the accuracy and reproducibility requirements. (Specific accuracy/reproducibility values are not provided).
Usability Testing (IV-LINQ)Usability testing is performed to validate the IV-LINQ workflow of CAAS Workstation and demonstrated that the user is able to use IV LINQ for the purpose it was developed for.

2. Sample Size Used for the Test Set and Data Provenance:

The document does not specify the sample size used for any test sets, nor does it provide information on the data provenance (e.g., country of origin, retrospective or prospective) for training or testing.

3. Number of Experts Used to Establish Ground Truth and Qualifications:

The document does not specify the number of experts used to establish ground truth or their qualifications for any part of the testing.

4. Adjudication Method for the Test Set:

The document does not mention any adjudication method used for a test set.

5. Multi Reader Multi Case (MRMC) Comparative Effectiveness Study:

The document does not mention a Multi Reader Multi Case (MRMC) comparative effectiveness study being done, nor does it provide any effect size for human reader improvement with or without AI assistance.

6. Standalone Performance Study:

The document implies a standalone performance for the algorithm through statements like "System testing showed that the system requirements were implemented correctly" and "proper functioning of the algorithms is validated." However, it does not explicitly detail a dedicated standalone study with specific metrics. The focus is on the software's functionality and accuracy of its calculations.

7. Type of Ground Truth Used:

The document describes "validation approaches" and "proper functioning of the algorithms," and "accuracy and reproducibility requirements" for length measurements. This suggests the ground truth was likely established through:

  • Reference measurements or calculations for quantitative aspects (e.g., vessel dimensions, stenosis quantification).
  • Comparison to accepted standards or methods for qualitative aspects or algorithmic outputs.

However, the document does not explicitly state the specific type of ground truth used (e.g., expert consensus, pathology, outcomes data).

8. Sample Size for the Training Set:

The document does not provide any information regarding the sample size used for the training set.

9. How Ground Truth for the Training Set Was Established:

As no training set size is provided, the document does not explain how ground truth for a training set was established.

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized depiction of an eagle with three human profiles incorporated into its design. The profiles are arranged in a way that they form the body and wings of the eagle. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the eagle symbol.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

March 11, 2016

Pie Medical Imaging B.V. % Ms. Florie Daniels Regulatory Affairs Coordinator Philipsweg 1 Maastricht, Limburg 6227 AJ THE NETHERLANDS

Re: K151780

Trade/Device Name: CAAS Workstation Regulation Number: 21 CFR 892.1600 Regulation Name: Angiographic x-ray system Regulatory Class: II Product Code: IZI, LLZ Dated: February 1, 2016 Received: February 8, 2016

Dear Ms. Daniels:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{1}------------------------------------------------

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours.

Michael D.'Hara

Robert Ochs, Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

For

Enclosure

{2}------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

510(k) Number (if known) K151780

Device Name CAAS Workstation

Indications for Use (Describe)

CAAS Workstation features segmentation of cardiovascular structures, 3D reconstruction of vessel segments and catheter path based on multiple angiographic images, measurement and reporting tools to facilitate the following use:

  • · Calculate the dimensions of cardiovascular structures;
  • · Quantify stenosis in coronary and peripheral vessels;
  • · Quantify the motion of the left and right ventricular wall;
  • · Perform density measurements;
  • · Determine C-arm position for optimal imaging of cardiovascular structures;
  • · Enhance stent visualization and measure stent dimensions;
  • · Co-registration of angiographic X-Ray images with IVUS and OCT images.

CAAS Workstation is intended to be used by or under supervision of a cardiologist or radiologist. When the results provided by CAAS Workstation are used in a clinical setting to support diagnoses and for assistance during intervention of cardiovascular conditions, the results are explicitly not to be regarded as the sole, irrefutable basis for clinical decision making.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

Form Approved: OMB No. 0910-0120

Expiration Date: January 31, 2017

See PRA Statement below.

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510(k) SummaryCAAS Workstation[GEN1934]v3.0
Submitter/Owner NamePie Medical Imaging BV
AddressPhilipsweg 1, 6227 AJ Maastricht, The Netherlands
Phone Number+31 43 32 81 328
Fax Number+31 43 32 81 329
Contact Person:Florie Daniels, Regulatory Affairs Coordinator
Email AddressFlorie.Daniels@pie.nl
Preparation Date26-Jun-2015
Trade NameCAAS Workstation
Common NameCardiovascular Angiographic Analysis System
Classification:Classification Name: Angiographic X-ray SystemRegulation Class: Class IIRegulation number: 21 CFR 892.1600Classification Product Code: IZISubsequent Product Code: LLZ
Predicate DevicesCAAS Workstation (K133993, Angiographic X-ray System, 21 CFR 892.1600, IZI, LLZ )
Volcano Angio-IVUS Mapping system (K060483, Echocardiograph, 21 CFR 870.2330, IYO, IZI)
Device DescriptionCAAS Workstation is designed as a stand-alone modular software product forviewing and quantification of X-ray angiographic images intended to run on a PCwith a Windows operating system. CAAS Workstation contains the analysismodules QCA, QCA3D, QVA, LVA, RVA and StentEnhancer of the previouslycleared predicate device CAAS Workstation (K133993) for calculatingdimensions of coronary and peripheral vessels and the left and right ventricles,quantification of stenosis, performing density measurements, determination ofoptimal C-arm position for imaging of vessel segments and functionality toenhance the visualization of a stent and to measure stent dimension. Semi-automatic contour detection forms the basis for the analyses.Functionality to co-register X-ray angiographic images and intravascular imagingtechniques (such as intravascular ultrasound and optical coherence tomography)is added by means of the analysis module IV-LINQ. With co-registration acommon frame of intravascular imaging techniques with X-ray angiographicimages is provided using a three-dimensional model. This functionality is basedon the Volcano Angio-IVUS Mapping system (K060483).In the IV LINQ workflow the user has to select two angiographic X-ray images inDICOM format. The user indicates a catheter path starting at the imaging tip.This path can be optimized manually by adding, deleting or moving control pointon the drawn path. After the catheter path is drawn in both angiographic X-rayimages, a 3D reconstruction of the catheter path is calculated.
The user then has to select one IVUS or OCT dataset in DICOM format or the data is streamed from the intravascular imaging console with a DVI streamer. The IVUS or OCT pullback must be acquired using a motorized pullback device. After the 3D catheter path from X-ray angiographic images is calculated and the IVUS or OCT pullback is loaded, IV-LINQ co-registers each IVUS or OCT frame with a position on the 3D catheter path using a distance mapping algorithm. On intravascular images diameter and area measurements can be performed.
The quantitative results of CAAS Workstation support diagnosis and intervention of cardiovascular conditions.The analysis results are available on screen, and can be exported in various electronic formats.The functionality is independent of the type of vendor acquisition equipment.
Intended UseCAAS Workstation is a modular software product intended to be used by or under supervision of a cardiologist or radiologist in order to aid in reading, co-registering and interpreting cardiovascular X-Ray images to support diagnoses and for assistance during intervention of cardiovascular conditions.
Indications for UseCAAS Workstation features segmentation of cardiovascular structures, 3D reconstruction of vessel segments and catheter path based on multiple angiographic images, measurement and reporting tools to facilitate the following use:Calculate the dimensions of cardiovascular structures; Quantify stenosis in coronary and peripheral vessels; Quantify the motion of the left and right ventricular wall; Perform density measurements; Determine C-arm position for optimal imaging of cardiovascular structures; Enhance stent visualization and measure stent dimensions; Co-registration of angiographic X-Ray images with IVUS and OCT images. CAAS Workstation is intended to be used by or under supervision of a cardiologist or radiologist. When the results provided by CAAS Workstation are used in a clinical setting to support diagnoses and for assistance during intervention of cardiovascular conditions, the results are explicitly not to be regarded as the sole, irrefutable basis for clinical decision making.

{4}------------------------------------------------

Technological Characteristics Comparison

A comparison of the technological characteristics of the predicate and subject device is given the table below.

New DevicePredicate DevicePredicate Device
Device nameCAAS WorkstationCAAS WorkstationAngio-IVUS Mapping System
ManufacturerPie Medical ImagingPie Medical ImagingVolcano Corp.
510(k) number-K133993K060483
Data typeX-Ray Angiography data in DICOM format (vendor independent) IVUS data as videostream or in DICOM format (vendor independent) OCT data as DICOM format only (vendor independent)X-Ray Angiography data in DICOM format (vendor independent)X-Ray Angiography data in DICOM format (vendor independent) IVUS data in DICOM format
Import of PatientDataManual through keyboard Command line interfaceManual through keyboard Command line interfaceManual through keyboard
CenterlineDefinitionManual and semi-automatic centerline definition based contour detection of coronary andManual and semi-automatic centerline definition based contour detection of coronary and
New DevicePredicate DevicePredicate Device
Device nameCAAS WorkstationCAAS WorkstationAngio-IVUS Mapping System
ManufacturerPie Medical ImagingPie Medical ImagingVolcano Corp.
510(k) number-K133993K060483
peripheral vessel Manual and semi-automatic left ventricular contour definition Manual right ventricular contour definition Manual stent contour definition Contour correction and restriction Manual catheter path definitionperipheral vessel Manual and semi-automatic left ventricular contour definition Manual right ventricular contour definition Manual stent contour definition Contour correction and restrictionManual and semi-automatic centerline / catheter path definition
Image Display2D X-Ray image 3D reconstruction based on 2 X-Ray images 2D intravascular image Longitudinal intravascular reconstruction2D X-Ray image 3D reconstruction based on 2 X-Ray images2D X-Ray image 3D reconstruction based on 2 X-Ray images 2D intravascular image Longitudinal intravascular reconstruction
ImageAssessmentX-RayManual and automatic calibration Basic length, diameter, density and angle measurements Vessels and ventricle dimensions (diameters, areas, volumes) Automatic and manual stenosis assessment Left and right ventricular wall motion Left ventricular myocardium dimensions Enhanced stent visualization Stent dimensions Providing a common frame of reference for IVUS and OCT data with X-ray angiographic dataManual and automatic calibration Basic length, diameter, density and angle measurements Vessels and ventricle dimensions (diameters, areas, volumes) Automatic and manual stenosis assessment Left and right ventricular wall motion Left ventricular myocardium dimensions Enhanced stent visualization Stent dimensionsManual and automatic calibration Basic length, diameter, density and angle measurements
ImageAssessment -IVUS / OCTBasic diameter and area measurementsProviding a common frame of reference for IVUS data with X-ray angiographic data Basic diameter and area measurements
Storage ofResultsPrintout Images DICOM SC XML PDFPrintout Images DICOM SC XML PDFPrintout Images DICOM SC
OperatingSystemWindowsWindowsWindows

{5}------------------------------------------------

Besides IVUS images, also OCT images can be co-registered with IV LINQ. IV LINQ bases image co-registration on the length of the intravascular imaging pullback (either IVUS or OCT). This is similar as the basis for image coregistration in the predicate device Angio-IVUS Mapping System (K060483), which uses the length of the IVUS pullback. The length of an OCT pullback is calculated using the same acquisition information as for IVUS. For IVUS DICOM and IVUS video stream data the calculation of length is also based on the same acquisition information.

The differences in technological characteristics of the subject device compared to the predicate devices therefore do not effect the safety and effectivess of the device.

Conformance Standards The device complies with the following conformance standards:

  • ISO 14971:2007, Medical devices Application of risk management to . medical devices

{6}------------------------------------------------

NEMA PS 3.1 – 3.20 (2011), Digital Imaging and Communication inMedicine (DICOM) Set. (Radiology) IEC 62304 First edition 2006-05, Medical device software – Software lifecycle processes IEC 62336:2007, Medical devices - Application of usability engineering tomedical devices
Performance DataSystem requirements – derived from the intended use and indications for use – aswell as risk control measures are verified by system testing. System testingshowed that the system requirements were implemented correctly.For each analysis workflow a validation approach is created and the properfunctioning of the algorithms is validated.For analysis workflows already implemented in earlier versions of CAASWorkstation regression testing is performed to verify equivalence in numericalresults.The validation of the distance mapping algorithm used in IV LINQ demonstratedthat the length on which co-registration is based, meets the accuracy andreproducibility requirements.Usability testing is performed to validate the IV-LINQ workflow of CAASWorkstation and demonstrated that the user is able to use IV LINQ for thepurpose it was developed for.The test results demonstrate safety and effectiveness of CAAS Workstation inrelation to its intended use and that CAAS Workstation is considered as safe andeffective as the predicate devices.
Substantial EquivalenceThe analysis workflows QCA, QVA, LVA, RVA, QCA3D and StentEnhancer inthe previously cleared device CAAS Workstation (K133993) are available inCAAS Workstation and are the same in terms of intended use and indications foruse and have the same technological characteristic. The difference between thesetwo devices is that the analysis workflow 'IV-LINQ' has been added in CAASWorkstation. With the addition of the IV LINQ workflow, the new CAASWorkstation is, like the predicate CAAS Workstation (K133993), intended tosupport the interventional cardiologist and radiologist with diagnoses and assistthem during intervention of cardiovascular conditions.
IV-LINQ has similar intended use and indications for use as the Angio-IVUSMapping System (K060483). Technologically similar 3D reconstruction anddistance mapping methods are used to provide co-registration in Angio-IVUSMapping System as are used in IV-LINQ. Besides IVUS also OCT images can beco-registered with IV LINQ. OCT images are two-dimensional images createdusing back-reflecting light versus back-reflected sound waves in IVUS imaging.The image processing of OCT and IVUS images in IV LINQ is consideredtechnologically similar and as such does not affect the safety and effectiveness ofthe device when used as labeled. There is no difference in the clinical use of IVLINQ, which is providing a common frame of reference, related to the use ofOCT images versus IVUS images and the clinical use is therefore considered thesame as for the predicate Angio-IVUS Mapping System (K060483).
ConclusionThe testing reported in this 510(k) demonstrates that CAAS Workstation issubstantially equivalent to a combination of the predicate devices in terms ofintended use, indications for use, technological characteristics, measurements andoperating environment. As such CAAS Workstation is considered as safe andeffective as its predicate devices and performs as well as the predicate devices.

§ 892.1600 Angiographic x-ray system.

(a)
Identification. An angiographic x-ray system is a device intended for radiologic visualization of the heart, blood vessels, or lymphatic system during or after injection of a contrast medium. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II.